Skip to main content

Table 1 Demographic and clinical features of the patients at baseline

From: SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout

  Gout storytelling
N = 152
Control
N = 154
p value
  N (%) or mean (SD) N (%) or mean (SD)  
Age, in years 64.0 (8.3) 65.0 (8.0) 0.29
AA race/ethnicity 152 (100%) 154 (100%) 1.0
Marital status
 Single 38 (26%) 37 (25%) 0.39
 Married 59 (40%) 65 (43%)  
 Divorced 30 (20%) 32 (21%)  
 Widowed 9 (6%) 10 (7%)  
 Separated 13 (9%) 6 (4%)  
 Missing 3 (2%) 4 (3%)  
Annual income, US $
 < $20,000 0 (0%) 0 (0%) 0.90
 $20,000–$39,999 53 (37%) 57 (38%)  
 $40,000–$59,999 44 (31%) 45 (30%)  
 $60,000–$99,999 28 (20%) 26 (17%)  
 $100,000–$149,999 13 (9%) 16 (11%)  
 $150,000 and above 4 (3%) 5 (3%)  
  Missing 10 (7%) 5 (3%)  
Body mass index (BMI), kg/m2 32.9 (5.7) 32.9 (8.0) 0.98
Gout duration, in years 3.1 (1.0) 3.0 (0.9) 0.43
ACR/EULAR 2015 Gout classification criteria scorea 9.7 (4) 9.0 (3.4) 0.07
Primary outcome
  Mean ULT MPR with MEMSCap™ 89% (14%) 87% (16%) 0.36
  % With MPR ≥ 80% with MEMSCap™ 124 (84%) 119 (78%) 0.29
Secondary outcomes
 Voils self-reported non-adherence scaleb 1.60 (0.8) 1.40 (0.7) 0.03
 Proportion with pt.-reported current gout flare 27 (18%) 30 (20%) 0.79
 Serum urate, mg/dl 5.90 (1.8) 5.70 (1.7) 0.58
 SATMED side effects 14 (9.4%) 13 (8.8%) 1.0
 SATMED subscales
   Treatment effectiveness (0–100) 8.15 (3.2) 8.12 (3.7) 0.94
   Convenience of use (0–100) 9.37 (3.3) 9.54 (3.2) 0.65
   Impact on daily living/activities (0–100) 8.85 (2.4) 8.55 (3.7) 0.43
   Medical care (0–100) 5.97 (2.4) 5.81 (2.5) 0.57
   Undesirable side effects (0–100) 11.69 (1.1) 11.53 (1.7) 0.35
   Global satisfaction (0–100) 10.36 (2.1) 9.69 (2.9) 0.02
 Total SATMED composite score (0–100) 79.98 (14.6) 78.29 (19.4) 0.39
Gout-specific HRQOL on GAQ-GIS subscales
 Gout concern overall 52.22 (27) 48.49 (27.2) 0.23
 Gout medication side effects 39.14 (24.3) 39.38 (24.7) 0.94
 Unmet gout treatment need 36.32 (18.8) 34.97 (20.3) 0.55
 Well-being during attack 47.25 (25.5) 45.81 (25.3) 0.62
 Gout concern during attack 55.58 (23.8) 49.58 (25.7) 0.03
PEMAT-A/V
 Understandability (items 1–13) 92.16 (12.5) 91.26 (15.7) 0.58
 Accountability (items 14–17) 91.12 (16.6) 88.64 (21.0) 0.25
BRFSS alcohol use in last 30 days
 Days per week with ≥ 1 alcohol drinks 1.61 (3.5) 1.95 (4.2) 0.43
 Days per month with ≥ 1 alcohol drinks 3.68 (9.9) 3.66 (6.4) 0.98
 Alcohol drinks per day, median (interquartile range)c 0 (0, 2) 0 (0, 2) 0.56
 Alcohol drinks ≥ 5 alcohol drinks 0.81 (2.8) 0.91 (3.2) 0.78
 Largest number of alcohol drinks on any occasion 1.72 (3.7) 1.4 (2.1) 0.36
Baseline gout flares
 Last/previous 1 month 1.40 (1.9) 1.40 (2.8) 0.88
 Last/previous 2 month 2.30 (3.7) 2.50 (5.5) 0.79
Pill count 28.0 (44.5) 30.7 (49.7) 0.79
  1. aAll patients met the 1977 Preliminary American College of Rheumatology (ACR) gout classification criteria; 87% in each group also met the 2015 ACR-European League Against Rheumatism (EULAR) criteria (a total score of 8 or higher or urate crystals present in the synovial/joint fluid or in tophus)
  2. bSelf-reported non-adherence scale by Voils et al.; the total score reflects the respondents’ agreement with three ordinal scaled items about non-adherence, ranging from 1 (strongly disagree) to 5 (strongly agree); cmedian (interquartile range) provided for alcohol drinks/day, due to extremely high values for some individuals, which makes the median a better measure of central tendency than the mean
  3. AA African American, ULT urate-lowering therapy, MPR Medication Possession Ratio, SATMED Satisfaction with Medications Questionnaire, PEMAT-A/V Patient Education Materials Assessment Tool for Audiovisual Materials, SU serum urate, HRQOL health-related quality of life, GAQ-GIS Gout Impact scale of the Gout assessment questionnaire, BRFSS Behavioral Risk Factor Surveillance System
  4. Significant p values are in bold; All p-values are based on student's t-test except for the median alcohol drinks/day, which is based on the Wilcoxon signed-rank test